This Core Center of Excellence in Hematology (CCEH) is designed to overcome feasibility issues that limit the ability of individual investigators to apply state-of-the-art methods to isolate, characterize, manipulate and functionally analyze hematopoietic cells. This is achieved through services provided by the five biomedical research cores: B, large scale cell processing; C, clonal analysis; D,vector production; E. xenografting; and F, canine resources. The Administrative Core (Core A) provides managerial, scientific, and budgetary oversight for these core activities. In addition Core A is responsible for administrating the Pilot and Feasibility (P&F) studies program and the Enrichment Program. These two programs are supported by program income derived from charge back fees levied for core services. Management of program income is also under the purview of Core A. The Enrichment Program, under the direction of the Administrative Core, serves the hematology research community by sponsoring 3-6 outside speakers per year to present at the well-established Clinical Research Division Monday noon lecture series. This lecture series also provides CCEH members with an opportunity to formally present their research, which Is a requirement for appointments and promotions. Lectures are held every Monday at the FHCRC and usually attract between 50-75 people. Lectures are also made available through a live feed to the UW, Children's Hospital, Seattle Cancer Care Alliance, Seattle VA, University of British Columbia, and University of Victoria. The live feed allows audience participation at the remote sites. Faculty members attending these lectures will receive CME credits.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK056465-14
Application #
8566002
Study Section
Special Emphasis Panel (ZDK1-GRB-G (O3))
Project Start
1999-09-15
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
14
Fiscal Year
2012
Total Cost
$184,129
Indirect Cost
$77,416
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Venkataraman, G M; Kennedy, L J; Little, M-T E et al. (2017) Thirteen novel canine dog leukocyte antigen-88 alleles identified by sequence-based typing. HLA 90:165-170
Hay, Kevin A; Hanafi, Laïla-Aïcha; Li, Daniel et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295-2306
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020
Burwick, Nicholas; Zhang, Michael Y; de la Puente, Pilar et al. (2017) The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Leuk Res 55:23-32
Gust, Juliane; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 7:1404-1419
Aranda-Orgilles, Beatriz; Saldaña-Meyer, Ricardo; Wang, Eric et al. (2016) MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis. Cell Stem Cell 19:784-799
Laszlo, George S; Harrington, Kimberly H; Gudgeon, Chelsea J et al. (2016) Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget 7:43281-43294
Adair, Jennifer E; Waters, Timothy; Haworth, Kevin G et al. (2016) Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. Nat Commun 7:13173
Yeung, Cecilia C S; Deeg, H Joachim; Pritchard, Colin et al. (2016) Jumping translocations in myelodysplastic syndromes. Cancer Genet 209:395-402
Rufener, Gregory A; Press, Oliver W; Olsen, Philip et al. (2016) Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer Immunol Res 4:509-19

Showing the most recent 10 out of 259 publications